MX9303981A - Nuevos compuestos farmaceuticos, proceso para su preparacion y composicion farmaceutica que los contiene. - Google Patents

Nuevos compuestos farmaceuticos, proceso para su preparacion y composicion farmaceutica que los contiene.

Info

Publication number
MX9303981A
MX9303981A MX9303981A MX9303981A MX9303981A MX 9303981 A MX9303981 A MX 9303981A MX 9303981 A MX9303981 A MX 9303981A MX 9303981 A MX9303981 A MX 9303981A MX 9303981 A MX9303981 A MX 9303981A
Authority
MX
Mexico
Prior art keywords
formula
heterocyclyl group
aromatic heterocyclyl
alkyl
preparation
Prior art date
Application number
MX9303981A
Other languages
English (en)
Inventor
David Haigh
John Thomas Sime
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929214185A external-priority patent/GB9214185D0/en
Priority claimed from GB929227030A external-priority patent/GB9227030D0/en
Priority claimed from GB939311027A external-priority patent/GB9311027D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9303981A publication Critical patent/MX9303981A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporciona un compuesto de la fórmula (I): a1-x-(CH2)n-o-A2-A3-Y.R2; o una forma tautomérica de la misma y/o una sal farmacéuticamente aceptable de la misma, y/o un solvato farmacéuticamente aceptable de la misma, en la que: A1 representa un grupo heterociclilo aromático sustituido o sin sustituir; A2 representa un anillo de benceno que tiene tres sustituyentes opcionales; A3 representa una porción de la fórmula -(CH2)m-CH(OR1)- en la que R1 representa alquilo, arilo, aralquilo o alquilcarbonilo sustituido o sin sustituir y m representa un número entero en la gama de 1 a 5, o A3 representa una porción de la fórmula -(CH2)m-1-CHC(OR1)- en la que R1 y m son como se definieron en lo anterior; R2 representa OR3 en la que R3 representa hidrógeno, alquilo, arilo o aralquilo o R2 representa un grupo heterociclilo aromático o -NR4R5 en el que R4 y R5 representan cada uno independientemente hidrógeno, alquilo o alquilcarbonilo o R4 y R5 junto con el átomo de nitrógeno la cual están unidos, forman un anillo heterocíclico, con la condición de que R2 represente un grupo heterociclilo aromático, solamente cuando y como se definió en lo siguiente representa un enlace.
MX9303981A 1992-07-03 1993-07-01 Nuevos compuestos farmaceuticos, proceso para su preparacion y composicion farmaceutica que los contiene. MX9303981A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929214185A GB9214185D0 (en) 1992-07-03 1992-07-03 Novel compounds
GB929227030A GB9227030D0 (en) 1992-12-29 1992-12-29 Novel compounds
GB939311027A GB9311027D0 (en) 1993-05-28 1993-05-28 Novel compounds

Publications (1)

Publication Number Publication Date
MX9303981A true MX9303981A (es) 1994-04-29

Family

ID=27266276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303981A MX9303981A (es) 1992-07-03 1993-07-01 Nuevos compuestos farmaceuticos, proceso para su preparacion y composicion farmaceutica que los contiene.

Country Status (19)

Country Link
US (2) US6048883A (es)
EP (2) EP1000938A1 (es)
JP (1) JPH07508747A (es)
KR (1) KR950702545A (es)
CN (2) CN1042532C (es)
AT (1) ATE207470T1 (es)
AU (1) AU678974B2 (es)
CA (1) CA2139442A1 (es)
CZ (1) CZ1095A3 (es)
DE (1) DE69331010D1 (es)
FI (1) FI950016A (es)
HU (1) HUT71247A (es)
MX (1) MX9303981A (es)
NO (2) NO305318B1 (es)
NZ (1) NZ253742A (es)
PL (2) PL174610B1 (es)
RU (1) RU2134686C1 (es)
SK (1) SK695A3 (es)
WO (1) WO1994001420A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311661D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9311644D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9315148D0 (en) * 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
GB9326171D0 (en) * 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) * 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
JPH10503508A (ja) * 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｉｉ型糖尿病の治療において有用なベンゾオキサゾールおよびピリジン誘導体
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
UA67743C2 (uk) 1997-06-18 2004-07-15 Смітклайн Бічам П.Л.С. Фармацевтична композиція, що містить тіазолідиндіон і сульфонілсечовину, для лікування діабету
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
CN100376560C (zh) 1997-10-27 2008-03-26 雷迪实验室有限公司 新型三环化合物和其作为药物的用途;其制备方法和包含该化合物的药物组合物
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
RU2247722C2 (ru) 1997-10-27 2005-03-10 Др. Редди`З Лабораториз Лимитед Производные арилкарбоновых кислот, способы их получения, фармацевтическая композиция на их основе, способы лечения и предупреждения различных заболеваний, промежуточные соединения и способы их получения
US6265401B1 (en) 1997-10-27 2001-07-24 Reddy-Cheminor, Inc. Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
GB2380997B (en) * 1997-10-27 2003-07-02 Reddys Lab Ltd Dr Novel aryl-oxysubstituted alkyl carboxylic acids; process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) * 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
AU768994B2 (en) 1998-11-12 2004-01-15 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
DZ2937A1 (fr) 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
US7000106B2 (en) * 1999-03-26 2006-02-14 Siemens Communications, Inc. Methods and apparatus for kernel mode encryption of computer telephony
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
CA2382966A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
SE9904415D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New process
MEP32408A (en) * 2000-01-19 2010-10-10 Cadila Healthcare Ltd Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
WO2001055086A1 (en) * 2000-01-28 2001-08-02 Novo Nordisk A/S Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
US6509374B2 (en) 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6559335B2 (en) 2000-09-22 2003-05-06 Dr. Reddy's Laboratories Limited Process for the preparation of 3-aryl-2-hydroxy propanoic acid
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
CZ20033037A3 (cs) 2001-05-15 2004-06-16 F. Hoffmann-La Roche Ag Karboxylové kyselinou odvozené od substituovaných oxazolových derivátů pro použití jako PPAR-alfa a -gama aktivátory při léčbě diabetu
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
EP1452521A4 (en) 2001-08-17 2007-03-14 Eisai R&D Man Co Ltd CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR
US7220877B2 (en) 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
JP2005518408A (ja) 2001-12-29 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 異常脂肪血症を治療するための、ｇｌｐ−１化合物と他の薬物との組み合わせ使用
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
RU2296754C2 (ru) * 2002-08-30 2007-04-10 Ф.Хоффманн-Ля Рош Аг НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPAR α И PPAR γ
SI1539746T1 (sl) 2002-09-12 2007-04-30 Hoffmann La Roche Spojine n-substituirane-1h-indol-5-propionske kisline kot agonisti ppar, ki so uporabne za zdravljenje diabetesa
KR100713266B1 (ko) 2002-11-25 2007-05-04 에프. 호프만-라 로슈 아게 인돌릴 유도체
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
US6653334B1 (en) 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
WO2004103959A2 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
WO2006090915A1 (en) * 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
WO2008117982A1 (en) * 2007-03-28 2008-10-02 Crystal Genomics, Inc. Heterocyclic carboxylic acid derivatives and pharmaceutical composition for inhibiting lipid accumulation containing same
US20100274022A1 (en) * 2007-04-26 2010-10-28 Pharmafrontier Co., Ltd. G protein-coupled receptor inhibitor and pharmaceutical product
MX350611B (es) 2011-01-31 2017-09-11 Cadila Healthcare Ltd Tratamiento para la lipodistrofia.
AU2013387996B2 (en) 2013-04-22 2015-12-10 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (NAFLD)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (es) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
CN103467406B (zh) * 2013-09-03 2014-12-17 浙江医药高等专科学校 卤素取代的四氮唑羧酸类化合物、其制备方法和用途
CN103467408B (zh) * 2013-09-03 2015-01-21 浙江医药高等专科学校 一类四氮唑羧酸类化合物及其用途
CN103467405B (zh) * 2013-09-03 2015-01-07 浙江医药高等专科学校 一类四氮唑羧酸类化合物、其制备方法和用途
CN103467409B (zh) * 2013-09-03 2015-01-07 浙江医药高等专科学校 取代的四氮唑羧酸类化合物及其用途
CN103467407B (zh) * 2013-09-03 2015-04-22 浙江医药高等专科学校 四氮唑羧酸类化合物及其用途
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
ES2894261T3 (es) 2016-12-09 2022-02-14 Cadila Healthcare Ltd Tratamiento de la colangitis biliar primaria

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
SK695A3 (en) 1995-07-11
CN1042532C (zh) 1999-03-17
HUT71247A (en) 1995-11-28
NO950009D0 (no) 1995-01-02
ATE207470T1 (de) 2001-11-15
EP1000938A1 (en) 2000-05-17
NO950009L (no) 1995-03-02
NO305318B1 (no) 1999-05-10
CZ1095A3 (en) 1995-10-18
PL174610B1 (pl) 1998-08-31
DE69331010D1 (de) 2001-11-29
AU678974B2 (en) 1997-06-19
CN1215724A (zh) 1999-05-05
RU2134686C1 (ru) 1999-08-20
NZ253742A (en) 1997-06-24
RU94046169A (ru) 1996-10-27
CN1095716A (zh) 1994-11-30
FI950016A (fi) 1995-03-02
HU9500006D0 (en) 1995-03-28
US6048883A (en) 2000-04-11
JPH07508747A (ja) 1995-09-28
NO990227D0 (no) 1999-01-19
FI950016A0 (fi) 1995-01-02
KR950702545A (ko) 1995-07-29
EP0648212A1 (en) 1995-04-19
AU4506893A (en) 1994-01-31
EP0648212B1 (en) 2001-10-24
PL176885B1 (pl) 1999-08-31
CA2139442A1 (en) 1994-01-20
NO990227L (no) 1995-03-02
WO1994001420A1 (en) 1994-01-20
US5869495A (en) 1999-02-09
PL307087A1 (en) 1995-05-02

Similar Documents

Publication Publication Date Title
MX9303981A (es) Nuevos compuestos farmaceuticos, proceso para su preparacion y composicion farmaceutica que los contiene.
MX9302088A (es) Derivados de alfa-tiocarbonilo y alfa-halocarbonilo, proceso para su preparacion y composicion farmaceutica que los comprende.
ECSP034660A (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
ES2192081T3 (es) Derivados de purina antivirales.
ATE102193T1 (de) Thiazolidinedionederivate.
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
ES2195933T3 (es) Nuevos derivados de flavonas, xantonas y cumarinas.
FI834692A0 (fi) Dihydropyridiner
GB1129072A (en) Benzofuran and indole derivatives
KR880012594A (ko) 벤조- 및 티에노-3,4-디하이드로-피리딘유도체, 이의 제조방법 및 이들 화합물을 함유하는 약제학적 조성물
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
KR860004045A (ko) 폴리사이클릭화합물의 제조방법 및 그 약학적 제제
ES2038532B1 (es) Procedimiento de preparacion de nuevos derivados de 2-piperacinilbecimidazol.
ES2046528T3 (es) Derivados heterotetraciclicos de lactamas, proceso para su preparacion y composiciones farmaceuticas a base de los mismos.
KR880008995A (ko) 2-알킬설피닐-4(3h)-퀴나졸리논 유도체, 이의 제조방법 및 약학적 조성물
HUT51629A (en) Process for producing new, heterocyclically substituted 5,7-dihydro-pyrrolo(3,2-f)-benzoxazole-6-one derivatives as well as pharmaceutical preparations containing such compounds
KR910007939A (ko) 헤테로사이클릭 화합물 및 이의 제조방법
GB1074744A (en) Improvements in or relating to substituted 9,10-dihydro-4h-benzo[4,5]cyclo-hepta[1,2-b]thiophenes
GB1192140A (en) New Indane-Diones and their Preparation
GB826830A (en) Derivatives of aminoethyl (2,5-endomethylene-benzhydryl) ether
GB2311781A (en) Piperazine 2,5 dione derivatives as modulators of multi-drug resistance
NO976101L (no) Nye ellipticinforbindelser, en fremgangsmÕte ved deres fremstilling, samt farmas°ytiske blandinger som inneholder dem
AR000267A1 (es)

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees